Cancer Genetics, Inc. (CGI) provides DNA-based cancer diagnostics and services to medical institutions. The Company's tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also provide a comprehensive range of non-proprietary oncology-focused tests and laboratory services. CGI’s tests and reference laboratory provide critical genomic information to healthcare professionals as well as biopharma and biotech. The Company's reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited.

Type
Public
HQ
Rutherford, US
Founded
1999
Size (employees)
142 (est)
Cancer Genetics was founded in 1999 and is headquartered in Rutherford, US
Report incorrect company information

Key People/Management at Cancer Genetics

Jay Roberts

Jay Roberts

Interim Chief Executive Officer & COO

Cancer Genetics Office Locations

Cancer Genetics has offices in Hyderabad, Rutherford, Morrisville, Los Angeles and in 1 other location
Rutherford, US (HQ)
Complex 201 Route 17 North
Los Angeles, US
Health Research Association 1640 Marengo St
Morrisville, US
133 Southcenter Ct
Shanghai, CN
Zhong Guo Yi Dong ( Cai Lun Lu )
Show all (5)
Report incorrect company information

Cancer Genetics Financials and Metrics

Cancer Genetics Financials

Cancer Genetics's revenue was reported to be $27.05 m in FY, 2016 which is a 49.9% increase from the previous period.
USD

Revenue (Q2, 2017)

6.6 m

Gross profit (Q2, 2017)

2.6 m

Gross profit margin (Q2, 2017), %

38.9%

EBIT (Q2, 2017)

(3.1 m)

Market capitalization (20-Apr-2018)

22.8 m

Cash (30-Jun-2017)

6.2 m

EV

18.6 m
Cancer Genetics's current market capitalization is $22.8 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

6.6 m10.2 m18 m27 m

Revenue growth, %

54%77%50%

Cost of goods sold

4.9 m8.5 m14.1 m17.1 m

Gross profit

1.7 m1.7 m3.9 m9.9 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

1.7 m1.4 m1.5 m3.2 m4.4 m4.2 m4 m6.1 m7 m6.8 b7 m6.6 m

Cost of goods sold

1.2 m1.3 m1.5 m2.6 m3.1 m3.1 m3.1 m4.1 m4.3 m4.4 b4.2 m4 m

Gross profit

493.8 k140.3 k8.6 k656.1 k1.2 m1.1 m897.1 k2 m2.7 m2.3 b2.8 m2.6 m

Gross profit Margin, %

29%10%1%20%28%26%22%32%39%34%40%39%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

49.5 m25.6 m19.5 m9.5 m

Current Assets

51.9 m31.8 m28.2 m23.4 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

9.9 m41.3 m23.7 m19.9 m13.3 m10.6 m10.7 m9.7 m6.2 m

Current Assets

12.2 m44.1 m31.1 m3.8 m23.5 m24.5 m26.6 m24.4 m21.9 m

PP&E

810.4 k1.3 m3.9 m5.9 m5.4 m4.9 m4.8 m4.7 m

Goodwill

3.2 m3.2 m12 m12 m12 m12 m12 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(12.4 m)(16.6 m)(20.2 m)(15.8 m)

Depreciation and Amortization

311.2 k810.2 k1.5 m2 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(2.5 m)(6.7 m)

Depreciation and Amortization

227.4 k96.8 k214.5 k487.7 k347.7 k679.6 k971.2 k518 k1 m1.5 m534 k981 k

Purchases of PP&E

(72.8 k)(144 k)(385.2 k)(944.4 k)(83.1 k)(257.5 k)(439.7 k)(319 k)(319 k)(345 k)(178 k)(400 k)

Cash From Investing Activities

(175.6 k)(6.2 m)(6.4 m)(10.9 m)(123.2 k)5.7 m4.6 m(358 k)(405 k)(472 k)(209 k)(663 k)
USDY, 2017

EV/EBIT

-6 x

Financial Leverage

2.2 x
Show all financial metrics
Report incorrect company information